Unknown

Dataset Information

0

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages.


ABSTRACT:

Background

The difficulties of early diagnosis of colorectal cancer (CRC) result in a high mortality rate. The ability to predict the response of a patient to surgical resection or chemotherapy may be of great value for clinicians when planning CRC treatments. Metabolomics is an emerging tool for biomarker discovery in cancer research. Previous reports have indicated that the metabolic profile of individuals can be significantly altered between CRC patients and healthy controls. However, metabolic changes in CRC patients at different treatment stages have not been explored.

Methods

To this end, we performed nuclear magnetic resonance (NMR)-based metabolomic analysis to determine metabolite aberrations in CRC patients before and after surgical resection or chemotherapy. In general, a total of 106 urine samples from four clinical groups, namely, healthy volunteers (n = 31), presurgery CRC patients (n = 25), postsurgery CRC patients (n = 25), and postchemotherapy CRC patients (n = 25), were collected and subjected to further analysis.

Results

In the present study, we identified five candidate metabolites, namely, N-phenylacetylglycine, succinate, 4-hydroxyphenylacetate, acetate, and arabinose, in CRC patients compared with healthy individuals, three of which were reported for the first time. Furthermore, approximately ten metabolites were uniquely identified at each stage of CRC treatment, serving as good candidates for biomarker panel selection.

Conclusion

In summary, these potential metabolite candidates may provide promising early diagnostic and monitoring approaches for CRC patients at different anticancer treatment stages.

SUBMITTER: Li Z 

PROVIDER: S-EPMC8855116 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages.

Li Zhuofei Z   Deng Xingming X   Luo Jun J   Lei Yunpeng Y   Jin Xinghan X   Zhu Jing J   Lv Guoqing G  

Frontiers in oncology 20220204


<h4>Background</h4>The difficulties of early diagnosis of colorectal cancer (CRC) result in a high mortality rate. The ability to predict the response of a patient to surgical resection or chemotherapy may be of great value for clinicians when planning CRC treatments. Metabolomics is an emerging tool for biomarker discovery in cancer research. Previous reports have indicated that the metabolic profile of individuals can be significantly altered between CRC patients and healthy controls. However,  ...[more]

Similar Datasets

| S-EPMC6508193 | biostudies-literature
| S-EPMC6781660 | biostudies-literature
| S-EPMC3586968 | biostudies-literature
| S-EPMC4905484 | biostudies-literature
| S-EPMC11763972 | biostudies-literature
| S-EPMC10044362 | biostudies-literature
| S-EPMC8266375 | biostudies-literature
| S-EPMC7491196 | biostudies-literature
| S-EPMC9002680 | biostudies-literature
| S-EPMC8234487 | biostudies-literature